

THESE FINANCIAL STATEMENTS FOR JUSHI HOLDINGS INC. ARE ALSO INCLUDED IN THE FORM 10-Q FOR

THE QUARTERLY PERIOD ENDED JUNE 30, 2024, FILED ON SEDAR IN ITS ENTIRETY

Table of Contents

For the quarterly period ended June 30, 2024

| Part I | FINANCIAL INFORMATION | Page |
|--------|---|------|
| Item 1 | Financial Statements | |
| | Condensed Consolidated Balance Sheets | 1 |
| | Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) | 2 |
| | Unaudited Condensed Consolidated Statements of Changes in Equity (Deficit) | 3 |
| | Unaudited Condensed Consolidated Statements of Cash Flows | 4 |
| | Notes to the Unaudited Condensed Consolidated Financial Statements | 6 |

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-O (this "report") may contain "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws, including Canadian securities legislation and United States ("U.S.") securities legislation (collectively, "forward-looking information") which are based upon the Company's current internal expectations, estimates, projections, assumptions and beliefs. All information, other than statements of historical facts, included in this report that address activities, events or developments that the Company expects or anticipates will or may occur in the future constitutes forward-looking information. Forward-looking information is often identified by the words, "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes, among others, information regarding: future business strategy; competitive strengths, goals, expansion and growth of the Company's business, operations and plans, including new revenue streams; the integration and benefits of recently acquired businesses or assets; roll out of new operations; the implementation by the Company of certain product lines; the implementation of certain research and development; the application for additional licenses and the grant of licenses that will be or have been applied for; the expansion or construction of certain facilities; the reduction in the number of our employees; the expansion into additional U.S. and international markets; any potential future legalization of adult use and/or medical marijuana under U.S. federal law; expectations of market size and growth in the U.S. and the states in which the Company operates; expectations for other economic, business, regulatory and/or competitive factors related to the Company or the cannabis industry generally; and other events or conditions that may occur in the future.

Readers are cautioned that forward-looking information is not based on historical facts but instead is based on reasonable assumptions and estimates of the management of the Company at the time they were provided or made and such information involves known and unknown risks, uncertainties, including our ability to continue as a going concern, and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as applicable, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information. Such factors include, among others: risks relating to U.S. regulatory landscape and enforcement related to cannabis, including political risks; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the cannabis industry; risks related to the economy generally; risks related to inflation, the rising cost of capital, and stock market instability; risks relating to pandemics and forces of nature; risks related to contracts with third party service providers; risks related to the enforceability of contracts; the limited operating history of the Company's history of operating losses and negative operating cash flows; reliance on the expertise and judgment of senior management of the Company; risks inherent in an agricultural business; risks related to co-investment with parties with different interests to the Company; risks related to proprietary intellectual property and potential infringement by third parties; risks relating to the Company's current amount of indebtedness; risks relating to the need to raise additional capital either through debt or equity financing; risks relating to the management of growth; costs associated with the Company being a publicly-traded company and a U.S. and Canadian filer; increasing competition in the industry; risks associated with cannabis products manufactured for human consumption including potential product recalls; reliance on key inputs, suppliers and skilled labor; reliance on manufacturers and contractors; risks of supply shortages or supply chain disruptions; cybersecurity risks; constraints on marketing products; fraudulent activity by employees, contractors and consultants; tax and insurance related risks; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcing judgments and effecting service outside of Canada; risks related to completed, pending or future acquisitions or dispositions, including potential future impairment of goodwill or intangibles acquired and/or post-closing disputes; sales of a significant amount of shares by existing shareholders; the limited market for securities of the Company; risks related to the continued performance of existing operations in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania, and Virginia; risks related to the anticipated openings of additional dispensaries or relocation of existing dispensaries; risks relating to the expansion and optimization of the cultivation and/or processing facilities in Massachusetts, Nevada, Ohio, Pennsylvania and Virginia; risks related to opening new facilities, which is subject to licensing approval; limited research and data relating to cannabis; risks related to challenges from governmental authorities with respect to the Company's tax credits; potential changes in federal policy and at regulatory agencies as a result of the upcoming United States 2024 presidential election; and risks related to the Company's critical accounting policies and estimates. Refer to Part I - Item 1A. Risk Factors in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on April 1, 2024 for more information.

Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on the forward-looking information contained in this report or other forward-looking statements made by the Company. Forward-looking information is provided and made as of the date of this Quarterly Report on Form 10-Q and the Company does not undertake any obligation to revise or update any forward-looking information or statements other than as required by applicable law.

Unless the context requires otherwise, references in this report to "Jushi," "Company," "we," "us" and "our" refer to Jushi Holdings Inc. and our subsidiaries.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

JUSHI HOLDINGS INC. CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars, except share amounts)

| | June 30, 2024 (unaudited) | | December 31, 2023 | | |
|--|------------------------------|-----------|-------------------|-----------|--|
| ASSETS | | | | | |
| CURRENT ASSETS: | | | | | |
| Cash and cash equivalents | \$ | 32,880 | \$ | 26,027 | |
| Restricted cash - current | | _ | | 3,128 | |
| Accounts receivable, net | | 2,227 | | 3,380 | |
| Inventory, net | | 39,446 | | 33,586 | |
| Prepaid expenses and other current assets | | 14,229 | | 15,514 | |
| Total current assets | | 88,782 | | 81,635 | |
| NON-CURRENT ASSETS: | | | | | |
| Property, plant and equipment, net | | 149,305 | | 159,268 | |
| Right-of-use assets - finance leases | | 61,091 | | 63,107 | |
| Other intangible assets, net | | 94,019 | | 95,967 | |
| Goodwill | | 30,910 | | 30,910 | |
| Other non-current assets | | 28,977 | | 30,358 | |
| Restricted cash - non-current | | 2,150 | | 2,150 | |
| Total non-current assets | | 366,452 | | 381,760 | |
| Total assets | \$ | 455,234 | \$ | 463,395 | |
| LIABILITIES AND EQUITY (DEFICIT) | | | | | |
| CURRENT LIABILITIES: | | | | | |
| Accounts payable | \$ | 16,035 | \$ | 15,383 | |
| Accrued expenses and other current liabilities | | 35,883 | | 44,070 | |
| Income tax payable | | 814 | | 5,190 | |
| Debt, net - current portion (including related party principal amounts of \$0 and \$3,298 as of June 30, 2024 and December 31, 2023, respectively) | | 9,954 | | 86,514 | |
| Finance lease obligations - current | | 8,958 | | 8,885 | |
| Derivative liabilities - current | | 2,082 | | 2,418 | |
| Total current liabilities | | 73,726 | | 162,460 | |
| NON-CURRENT LIABILITIES: | , | | | | |
| Debt, net - non-current (including related party principal amounts of \$19,360 and \$19,788 as of June 30, 2024 and December 31, 2023, respectively) | | 192,481 | | 126,041 | |
| Finance lease obligations - non-current | | 52,145 | | 52,839 | |
| Derivative liabilities - non-current | | 344 | | 220 | |
| Unrecognized tax benefits | | 127,139 | | 100,343 | |
| Other liabilities - non-current | | 33,183 | | 29,111 | |
| Total non-current liabilities | | 405,292 | | 308,554 | |
| Total liabilities | | 479,018 | | 471,014 | |
| COMMITMENTS AND CONTINGENCIES (Note 16) | <u> </u> | 477,010 | | 7/1,017 | |
| EQUITY (DEFICIT): | | | | | |
| Common stock, no par value: authorized shares - unlimited; issued and outstanding shares - 196,643,264 and 196,631,598 Subordinate Voting Shares as of June 30, 2024 and December 31, 2023, respectively | | _ | | _ | |
| Paid-in capital | | 506,353 | | 503,612 | |
| Accumulated deficit | | (530,137) | | (509,844) | |
| Total Jushi shareholders' deficit | | (23,784) | | (6,232) | |
| Non-controlling interests | | (23,70 F) | | (1,387) | |
| Total deficit | | (23,784) | | (7,619) | |
| | | | | | |

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars, except share and per share amounts)

| | Three Months | End | ed June 30, | Six Months E | nded June 30, | | |
|---|---------------|-----|-------------|----------------|---------------|-------------|--|
| | 2024 | | 2023 | 2024 | | 2023 | |
| REVENUE, NET | \$ 64,595 | \$ | 66,425 | \$ 130,054 | \$ | 136,298 | |
| COST OF GOODS SOLD | (32,029) | | (35,871) | (65,158) | | (75,803) | |
| GROSS PROFIT | 32,566 | | 30,554 | 64,896 | | 60,495 | |
| | | | | | | | |
| OPERATING EXPENSES | 24,162 | | 27,154 | 52,373 | | 59,606 | |
| | | | | | | | |
| INCOME FROM OPERATIONS | 8,404 | | 3,400 | 12,523 | | 889 | |
| | | | | | | | |
| OTHER INCOME (EXPENSE): | | | | | | | |
| Interest expense, net | (9,071) | | (9,790) | (18,615) | | (18,310) | |
| Fair value gain on derivatives | 5,312 | | 1,090 | 212 | | 9,120 | |
| Other, net | 2,746 | | (190) | 4,663 | | 519 | |
| Total other income (expense), net | (1,013) | | (8,890) | (13,740) | | (8,671) | |
| | | | | | | | |
| INCOME (LOSS) BEFORE INCOME TAX | 7,391 | | (5,490) | (1,217) | | (7,782) | |
| Income tax expense | (9,329) | | (8,546) | (19,076) | | (18,694) | |
| NET LOSS AND COMPREHENSIVE LOSS | \$ (1,938) | \$ | (14,036) | \$ (20,293) | \$ | (26,476) | |
| | | | | | | | |
| LOSS PER SHARE - BASIC | \$ (0.01) | \$ | (0.07) | \$ (0.10) | \$ | (0.14) | |
| Weighted average shares outstanding - basic | 195,138,473 | | 194,756,391 | 195,135,057 | | 194,405,562 | |
| LOSS PER SHARE - DILUTED | \$ (0.01) | \$ | (0.07) | \$ (0.10) | \$ | (0.14) | |
| Weighted average shares outstanding - diluted | 195,138,473 | | 194,756,391 | 195,135,057 | | 194,405,562 | |
| | | | | | | | |

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (DEFICIT)

(In thousands of U.S. dollars, except share amounts)

| | Six Months Eliaca dance 50, 2021 | | | | | | | | |
|--|----------------------------------|----|--------------------|----|----------------------|---|------|----------------------------------|---------------------------|
| | Subordinate Voting Shares | | Paid-In Capital | | cumulated Deficit | Total Just Sharehold Equity (Deficit | ers' | Non- Controlling Interests | Total Equity (Deficit) |
| Balances - January 1, 2024 | 196,631,598 | \$ | 503,612 | \$ | (509,844) | \$ (6, | 232) | \$ (1,387) | \$ (7,619) |
| Shares issued upon exercise of stock options | 3,333 | | 2 | | _ | | 2 | _ | 2 |
| Share-based compensation (including related parties) | _ | | 1,524 | | _ | 1, | 524 | _ | 1,524 |
| Issuance of warrants | _ | | 863 | | _ | | 863 | _ | 863 |
| Net loss | | | | | (18,355) | (18, | 355) | | (18,355) |
| Balances - March 31, 2024 | 196,634,931 | \$ | 506,001 | \$ | (528,199) | \$ (22, | 198) | \$ (1,387) | \$ (23,585) |
| Shares issued upon exercise of stock options | 8,333 | | 5 | | _ | | 5 | _ | 5 |
| Share-based compensation (including related parties) | _ | | 347 | | _ | | 347 | _ | 347 |
| Deconsolidation of Jushi Europe | _ | | _ | | _ | | _ | 1,387 | 1,387 |
| Net loss | | | _ | | (1,938) | (1, | 938) | | (1,938) |
| Balances - June 30, 2024 | 196,643,264 | \$ | 506,353 | \$ | (530,137) | \$ (23, | 784) | \$ — | \$ (23,784) |
| | | | | | | | | | |

Six Months Ended June 30, 2023

| | Subordinate Voting Shares | Paid-In Capital | Ac | ccumulated Deficit | Total Jushi Shareholders' Equity (Deficit) | Non- Controlling Interests | Total Equity (Deficit) |
|---|------------------------------|--------------------|----|-----------------------|---|----------------------------------|---------------------------|
| Balances - January 1, 2023 | 196,686,372 | \$ 492,020 | \$ | (444,742) | \$ 47,278 | \$ (1,387) | \$ 45,891 |
| Shares canceled upon forfeiture if restricted stock, net of restricted stock grants | (53,001) | _ | | _ | _ | _ | _ |
| Share-based compensation (including related parties) | _ | 2,311 | | _ | 2,311 | _ | 2,311 |
| Net loss | | | | (12,440) | (12,440) | | (12,440) |
| Balances - March 31, 2023 | 196,633,371 | \$ 494,331 | \$ | (457,182) | \$ 37,149 | \$ (1,387) | \$ 35,762 |
| Modification and reclassification of warrants | _ | 3,391 | | _ | 3,391 | _ | 3,391 |
| Share-based compensation (including related parties) | _ | 2,363 | | _ | 2,363 | _ | 2,363 |
| Net loss | | | | (14,036) | (14,036) | | (14,036) |
| Balances - June 30, 2023 | 196,633,371 | \$ 500,085 | \$ | (471,218) | \$ 28,867 | \$ (1,387) | \$ 27,480 |

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands of U.S. dollars)

| | Six Months Ended June 30, | | |
|---|------------------------------|----------|--|
| | 2024 | 2023 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | | | |
| Net loss | \$ (20,293) \$ | (26,476) | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | |
| Depreciation and amortization, including amounts in cost of goods sold | 14,213 | 13,964 | |
| Share-based compensation | 1,871 | 4,674 | |
| Fair value changes in derivatives | (212) | (9,120) | |
| Non-cash interest expense, including amortization of deferred financing costs | 3,303 | 2,913 | |
| Deferred income taxes and uncertain tax positions | 17,953 | 2,897 | |
| Gain on debt extinguishment | (399) | | |
| Gain on deconsolidation of Jushi Europe | (1,896) | | |
| Other non-cash items, net | (2,611) | 3,386 | |
| Changes in operating assets and liabilities: | | | |
| Accounts receivable | 1,393 | (764) | |
| Inventory | (6,679) | (9,311) | |
| Prepaid expenses and other current and non-current assets | (68) | (123) | |
| Accounts payable, accrued expenses and other current liabilities | 5,466 | 7,675 | |
| Net cash flows provided by (used in) operating activities | 12,041 | (10,285) | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | · | | |
| Payments for property, plant and equipment | (1,764) | (6,144) | |
| Proceeds from sale of property, plant and equipment | 2,723 | 916 | |
| Net cash flows provided by (used in) investing activities | 959 | (5,228) | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | - | | |
| Proceeds from exercise of options | 7 | _ | |
| Payments on promissory notes | (2,750) | | |
| Payments on acquisition related credit facility | (4,875) | | |
| Payments of finance leases | (1,212) | (2,681) | |
| Proceeds from mortgage loans | _ | 21,900 | |
| Payments of loan financing costs | _ | (250) | |
| Payments of mortgage loans | (143) | (110) | |
| Proceeds from other financing activities | 628 | 3,295 | |
| Payments of other financing activities | (930) | (1,725) | |
| Net cash flows (used in) provided by financing activities | (9,275) | 20,429 | |
| NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 3,725 | 4,916 | |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD | 31,305 | 27,146 | |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD | \$ 35,030 \$ | 32,062 | |

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)

(In thousands of U.S. dollars)

| | | Six Months Ended June 30, | | | |
|---|----|------------------------------|----|--------|--|
| | _ | 2024 | | 2023 | |
| | | | | | |
| SUPPLEMENTAL CASH FLOW INFORMATION: | | | | | |
| Cash paid for interest (excluding capitalized interest) | \$ | 14,998 | \$ | 14,787 | |
| Cash (received) paid for income taxes | \$ | (3,829) | \$ | 3,145 | |
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | | | | | |
| Capital expenditures | \$ | 1,246 | \$ | 2,360 | |
| Right-of-use assets from finance lease liabilities | \$ | 386 | \$ | 659 | |
| Issuance of second lien notes for settlement of accrued bonus | \$ | _ | \$ | 750 | |
| Issuance of second lien notes for debt exchange | \$ | 4,750 | \$ | _ | |
| Warrants issued for debt exchange | \$ | 863 | \$ | _ | |

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



1. NATURE OF OPERATIONS

Jushi Holdings Inc. (the "Company" or "Jushi") is incorporated under the British Columbia's Business Corporations Act. The Company is a vertically integrated, multi-state cannabis operator engaged in retail, distribution, cultivation, and processing in both medical and adult-use markets. As of June 30, 2024, Jushi, through its subsidiaries, owns or manages cannabis operations and/or holds licenses in the adult-use and/or medicinal cannabis marketplace in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania and Virginia. The Company's head office is located at 301 Yamato Road, Suite 3250, Boca Raton, Florida 33431, United States of America, and its registered address is Suite 1700, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2X8, Canada.

The Company is listed on the Canadian Securities Exchange ("CSE") and trades its subordinate voting shares ("SVS") under the ticker symbol "JUSH", and trades on the United States Over the Counter Stock Market ("OTCQX") under the symbol "JUSHF".

2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation and Consolidation

The financial statements have been prepared in accordance with generally accepted accounting principles in the United States ("GAAP") for interim financial information and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and footnotes. Actual results could differ materially from those estimates.

In the opinion of management, the unaudited condensed consolidated financial statements include all adjustments, of a normal recurring nature, that are necessary to present fairly the financial position, results of operations and cash flows of the Company for the periods, and at the dates, presented. The results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2023, which are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024 (the "2023 Form 10-K"), and was also filed on the System for Electronic Document Analysis and Retrieval ("SEDAR") on April 1, 2024. Consolidated balance sheet information as of December 31, 2023 presented herein is derived from the Company's audited consolidated financial statements for the year ended December 31, 2023.

Going Concern and Liquidity

As reflected in the 2023 Form 10-K, the Company used net cash of \$3,318 for operating activities for the year ended December 31, 2023, and as of that date, the Company's current liabilities exceeded its current assets by \$80,825. As of December 31, 2023 absent a refinancing, the Company would not meet its obligations within the next year and management believed that with a refinancing, the Company would meet its obligations. As a result, Management concluded as stated in the 2023 Form 10-K that substantial doubt existed about the Company's ability to continue as a going concern within the next twelve months from the date the 2023 financial statements were issued.

For the six months ended June 30, 2024, cash provided by operating activities was \$12,041, and as of June 30, 2024, the Company's current assets exceeded its current liabilities by \$15,056. As discussed in Note 8 - Debt and Note 19 - Subsequent Events, the Company refinanced its Acquisition Facility debt in July 2024, resulting in \$48,500 being reclassified from short-term debt to long-term debt as of June 30, 2024, since the Company expects to start making

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



scheduled principal payments in August 2025. As a result, the Company concluded that substantial doubt about the Company's ability to continue as a going concern no longer existed as of June 30, 2024.

The unaudited condensed consolidated financial statements contained herein have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty.

Summary of Significant Accounting Policies

The Company's significant accounting policies are described in Note 2 in the audited consolidated financial statements and notes thereto for the year ended December 31, 2023, which is included in the 2023 Form 10-K. Except as disclosed below, there have been no material changes to the Company's significant accounting policies.

Change in Accounting Estimate

In accordance with ASC 350, *Intangibles - Goodwill and Other*, the Company evaluates the remaining useful lives of intangible assets that are not being amortized each reporting period to determine whether events or circumstances continue to support an indefinite useful life. In May 2024, the Company sold one of its business licenses which was previously deemed to have an indefinite life. Furthermore, the Company continually evaluates its footprint and non-core assets, including licenses, as it executes its long-term strategies. In light of this, the Company determined that its business licenses no longer have indefinite useful lives. Additionally, the Company performed an impairment assessment immediately prior to the change and concluded that the business licenses were not impaired. As such, the Company commenced amortizing its business licenses with a gross value of \$82,401 effective June 1, 2024 on a straight-line basis over a 15-year period. Annual amortization is expected to be approximately \$5,493.

Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same such amounts shown in the consolidated statements of cash flows:

| | June 30, 2024 (unaudited) | December 31, 2023 | | |
|--|----------------------------------|-------------------|--------|--|
| Cash and cash equivalents | \$ 32,880 | \$ | 26,027 | |
| Restricted cash - current (1) | | | 3,128 | |
| Restricted cash - non-current | 2,150 | | 2,150 | |
| Cash, cash equivalents and restricted cash | \$ 35,030 | \$ | 31,305 | |

⁽¹⁾ Restricted cash - current primarily relates to the Manassas Mortgage. In April 2024, the lender released the entire \$3,128 of current restricted cash to the Company. Consequently, such cash is now unrestricted. Refer to Note 8 - Debt for more information.

Recent Accounting Pronouncements

Adoption of New Accounting Standards

In June 2020, the Financial Accounting Standards Board ("FASB") issued ASU 2020-06 *Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. This ASU also removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share calculation in certain areas. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. There was no impact to the consolidated financial statements upon adoption.*

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



In October 2021, the FASB issued ASU 2021-08, *Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.* The FASB issued guidance requires that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606. At the acquisition date, an acquirer should account for the related revenue contracts in accordance with Topic 606 as if it had originated the contracts. To achieve this, an acquirer may assess how the acquiree applied Topic 606 to determine what to record for the acquired revenue contracts. Generally, this should result in an acquirer recognizing and measuring the acquired contract assets and contract liabilities consistent with how they were recognized and measured in the acquiree's financial statements (if the acquiree prepared financial statements in accordance with generally accepted accounting principles). The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. There was no impact to the consolidated financial statements upon adoption.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. The FASB issued guidance clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023, although early adoption is permitted. There was no impact to the Company's consolidated financial statements upon adoption.

In March 2023, the FASB issued ASU 2023-01, *Leases (Topic 842): Common Control Arrangements*. The FASB issued guidance clarifies the accounting for leasehold improvements associated with common control leases, by requiring that leasehold improvements associated with common control leases be amortized by the lessee over the useful life of the leasehold improvements to the common control group (regardless of the lease term) as long as the lessee controls the use of the underlying asset through a lease. Additionally, leasehold improvements associated with common control leases should be accounted for as a transfer between entities under common control through an adjustment to equity if, and when, the lessee no longer controls the use of the underlying asset. The amendments in this ASU are effective for annual and interim periods beginning after December 15, 2023. There was no impact to the Company's consolidated financial statements upon adoption.

Accounting Standards Issued But Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which requires two primary enhancements of 1) disaggregated information on a reporting entity's effective tax rate reconciliation, and 2) information on incomes taxes paid. For public business entities, the new requirement will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating the effect of adopting this ASU.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



3. INVENTORY, NET

The components of inventory, net, are as follows:

| | June 30, 2024 (unaudited) | Dec | cember 31, 2023 |
|----------------------------------|----------------------------------|-----|-----------------|
| Cannabis plants | \$ 4,639 | \$ | 4,478 |
| Harvested cannabis and packaging | 11,628 | | 10,994 |
| Total raw materials | 16,267 | | 15,472 |
| Work in process | 6,270 | | 4,293 |
| Finished goods | 16,909 | | 13,821 |
| Total inventory, net | \$ 39,446 | \$ | 33,586 |

4. PREPAID EXPENSES AND OTHER CURRENT ASSETS

The components of prepaid expenses and other current assets are as follows:

| | June 30, (unaudi | | December 31, 2023 | | |
|---|---------------------|--------|--------------------------|--------|--|
| Employee retention credit receivable | \$ | 10,140 | \$ | 10,140 | |
| Prepaid expenses and deposits | | 3,439 | | 2,716 | |
| Assets held for sale | | _ | | 1,647 | |
| Other current assets | | 650 | | 1,011 | |
| Total prepaid expenses and other current assets | \$ | 14,229 | \$ | 15,514 | |

The Coronavirus Aid, Relief, and Economic Security Act, passed in March 2020 and subsequently amended in 2021, allowed eligible employers to take credits on certain amounts of qualified wages if the Company experienced either a full or partial suspension of operations due to COVID related government orders. During the year ended December 31, 2023, the Company, with guidance from a third-party specialist, determined it was entitled to employee retention credit ("ERC") claims of \$10,140 for previous business interruptions related to COVID and filed for such claims with the Internal Revenue Service ("IRS"). The ERC claims, which will be recognized in the consolidated statements of operations and comprehensive income (loss) when the Company receives the refunds of such claims from the IRS, were recorded as deferred income in Accrued expenses and other current liabilities, with an offsetting receivable amount in Prepaid expenses and other current assets within the consolidated balance sheets as of June 30, 2024 and December 31, 2023.

As of December 31, 2023, the Company determined that one of its grower processor facilities located in Nevada, with total carrying value of \$1,647, met the criteria to be classified as assets held for sale, and therefore was reclassified from Property, plant and equipment, net to assets held for sale, which was included in Prepaid expenses and other current assets in the consolidated balance sheets. In June 2024, the Company sold the grower processor facility in Nevada for a net gain of \$104. This amount was recorded in operating expenses in the consolidated statements of operation and comprehensive income (loss).

Additionally, during the three and six months ended June 30, 2024, the Company sold one of its business licenses in California which was previously written off, for a net gain of \$750. This amount was recorded in operating expenses in the consolidated statements of operation and comprehensive income (loss).

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



5. PROPERTY, PLANT AND EQUIPMENT

The components of property, plant and equipment ("PPE") are as follows:

| | ine 30, 2024 unaudited) | December 31, 2023 | | |
|---|----------------------------|-------------------|----------|--|
| Buildings and building components | \$ 88,151 | \$ | 88,527 | |
| Land | 12,956 | | 12,956 | |
| Leasehold improvements | 47,589 | | 46,660 | |
| Machinery and equipment | 27,051 | | 27,050 | |
| Furniture, fixtures and office equipment (including computer) | 21,957 | | 21,146 | |
| Construction-in-process | 193 | | 1,968 | |
| Property, plant and equipment, gross | 197,897 | | 198,307 | |
| Less: Accumulated depreciation | (48,592) | | (39,039) | |
| Property, plant and equipment, net | \$ 149,305 | \$ | 159,268 | |

Construction-in-process represents assets under construction for manufacturing and retail build-outs not yet ready for use.

Depreciation was \$4,974 and \$4,483 for the three months ended June 30, 2024 and 2023, respectively, and \$9,883 and \$9,295 for the six months ended June 30, 2024 and 2023, respectively. Interest expense capitalized to PPE totaled \$0 and \$222 for the three months ended June 30, 2024 and 2023, respectively, and \$0 and \$410 for the six months ended June 30, 2024 and 2023, respectively.

6. OTHER NON-CURRENT ASSETS

The components of other non-current assets are as follows:

| | June 30, 2024 (unaudited) | December 31, 2023 |
|-----------------------------------|------------------------------|--------------------------|
| Operating lease assets | \$ 16,669 | \$ 18,265 |
| Indemnification assets | 7,208 | 6,906 |
| Net deferred tax assets | 2,895 | 2,772 |
| Deposits and escrows - properties | 1,723 | 1,723 |
| Deposits - equipment | 422 | 422 |
| Equity investment (1) | | 200 |
| Other | 60 | 70 |
| Total other non-current assets | \$ 28,977 | \$ 30,358 |

The Company owns a 23.08% ownership interest in PV Culver City, LLC ("PVLLC"). The Company does not have significant influence over, and the Company does not have the right to vote or participate in the management of PVLLC and therefore the investment is measured at its fair value. Refer to Note 17 - Financial Instruments for more information relating to the fair value of this equity investment as of June 30, 2024, as well as loss on investment recorded.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



7. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

The components of accrued expenses and other current liabilities are as follows:

| | June 30, 2024 (unaudited) | December 31, 2023 |
|--|------------------------------|-------------------|
| Deferred income - ERC (1) | \$ 10,140 | \$ 10,140 |
| Goods received not invoiced | 5,155 | 5,019 |
| Accrued employee related expenses and liabilities | 5,300 | 4,175 |
| Operating lease obligations | 4,416 | 4,693 |
| Accrued sales and excise taxes | 2,474 | 2,388 |
| Accrued interest (2) | 2,094 | 4,106 |
| Deferred revenue (loyalty program) | 1,280 | 1,407 |
| Accrued professional and management fees | 729 | 986 |
| Accrued capital expenditures | | 702 |
| Acquisition-related milestone accrual (2) | | 4,167 |
| Contingent consideration liabilities (2) | | 817 |
| Other accrued expenses and current liabilities | 4,295 | 5,470 |
| Total accrued expenses and other current liabilities | \$ 35,883 | \$ 44,070 |

⁽¹⁾ Refer to Note 4 - Prepaid Expenses and Other Current Assets for more information.

8. DEBT

The components of the Company's debt are as follows:

| | Effective Interest Rate | Maturity Date | J | June 30, 2024 (unaudited) | Dece | ember 31, 2023 |
|--|----------------------------|------------------------------------|----|------------------------------|------|----------------|
| Principal amounts: | | | | | | |
| Second Lien Notes | 15% | December 2026 | \$ | 79,649 | \$ | 75,497 |
| Acquisition Facility (1) | 15% | December 2024 | | 55,250 | | 60,125 |
| Acquisition-related promissory notes payable | 8% - 16% | August 2024 - April 2027 | | 25,864 | | 35,716 |
| Mortgage loans | 6% - 11% | January 2027 - April 2028 | | 29,318 | | 29,456 |
| Total debt subject to scheduled repayments | | | | 190,081 | | 200,794 |
| Promissory notes payable to Sammartino (2) | 10% | September 2024 - September 2026 | | 21,500 | | 21,500 |
| Jushi Europe debt | n/a | March 2022 | | <u> </u> | | 3,298 |
| Total debt | | | | 211,581 | | 225,592 |
| Less: debt issuance costs and original issue discounts | | | | (9,146) | | (13,037) |
| Total debt, net | | | \$ | 202,435 | \$ | 212,555 |
| Debt, net - current portion | | | \$ | 9,954 | \$ | 86,514 |
| Debt, net - non-current portion | | | \$ | 192,481 | \$ | 126,041 |

This amount is related to Sammartino in connection with the acquisition of Nature's Remedy in September 2021. The acquisition-related milestone accrual of \$5,000 and accrued interest of \$2,677 as of June 30, 2024 was reclassified to other liabilities - non-current in the consolidated balance sheets, since the Company currently has no obligation to pay these amounts within the next 12 months from the balance sheet date. See further discussion of the Sammartino Matter in Note 16 - Commitments and Contingencies.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



- In July 2024, the Company refinanced the Acquisition Facility. Refer to Note 19 Subsequent Events for more information.
- This amount is related to the promissory notes issued to Sammartino in connection with the acquisition of Nature's Remedy in September 2021. The Company currently has no obligation to pay the principal and interest. See further discussion of the Sammartino Matter in Note 16 Commitments and Contingencies for more information.

Jushi Europe

On February 16, 2022, Jushi Europe filed a notice of over-indebtedness with the Swiss courts, and on May 19, 2022, the Swiss courts declared Jushi Europe's bankruptcy. As a result, the Company lost control of Jushi Europe's assets and liabilities since they are subject to oversight by the Geneva, Switzerland bankruptcy office. During the three and six months ended June 30, 2024, Jushi Europe was deconsolidated and its respective assets and liabilities were derecognized from the Company's consolidated financial statements, as the Company determined that it no longer has any obligation in relation to this subsidiary. Upon deconsolidation, the Company has no retained interest in Jushi Europe. As a result of these actions, the Company recognized a gain of \$1,896 in other income (expense), net in its consolidated statements of operations and comprehensive income (loss).

Second Lien Notes

On January 24, 2024, the Company entered into two Note Exchange Agreements (the "Note Exchange Agreements") with holders of approximately \$9,850 of the Company's unsecured debt (the "Existing Notes"). Upon closing of the transactions contemplated in the Note Exchange Agreements (the "Debt Exchange") on February 6, 2024, the holders of the Existing Notes delivered the Existing Notes to the Company for cancellation, and the Company: (1) issued to certain direct and beneficial holders of the Existing Notes an aggregate of \$4,750 principal amount of Second Lien Notes; (2) issued to certain direct and beneficial holders of the Existing Notes fully-detached warrants to purchase an aggregate of 1,800,000 of the Company's SVS, with each warrant having an exercise price of \$1.00 per SVS and an expiration of December 7, 2026; and (3) paid to the direct holders of the Existing Notes an aggregate of \$2,750 in cash. Refer to Note 10 - Equity for more information.

The Debt Exchange was accounted for as a debt extinguishment, and resulted in the Company recording a non-cash gain on debt extinguishment of \$399, which represents the difference between the reacquisition price of the Existing Notes and the net carrying amount of the Existing Notes prior to redemption. This amount was recorded in other income (expense), net in the consolidated statements of operation and comprehensive income (loss) during the first quarter of 2024.

Mortgage Loans

Arlington Mortgage

In December 2021, the Company entered into a \$6,900 mortgage loan agreement (the "Arlington Mortgage"), which is principally secured by the Company's retail property in Arlington, Virginia. The Arlington Mortgage bears a fixed interest rate of 5.875% per annum, payable monthly, and will mature in January 2027.

Dickson City Mortgage

In July 2022, the Company entered into a \$2,800 mortgage loan agreement (the "Dickson City Mortgage"), which is principally secured by the Company's retail property in Dickson City, Pennsylvania. The Dickson City Mortgage matures in July 2027 and bears interest at a variable rate equal to prime rate plus 2%. The interest rate as of June 30, 2024 was 10.5%.

Manassas Mortgage

In April 2023, the Company entered into a \$20,000 mortgage loan agreement (the "Manassas Mortgage"), which is principally secured by the Company's cultivation and manufacturing facility located in Manassas, Virginia. The Manassas

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



Mortgage is payable monthly and will mature in April 2028. The interest rate is variable and determined based on the 30-day average secured overnight financing rate plus 3.55%, with a floor rate of not less than 8.25%. The interest rate as of June 30, 2024 was 8.878%.

Financial Covenants

Acquisition Facility

The senior secured credit facility from Roxbury, LP, a portfolio company of SunStream Bancorp Inc., which is a joint venture sponsored by Sundial Growers Inc. (the "Acquisition Facility"), contains certain financial and other covenants with which the Company is required to comply, including covenants related to (i) minimum unrestricted cash and cash equivalents balance and (ii) minimum quarterly revenue. As of June 30, 2024, the Company was in compliance with all financial covenants contained in the Acquisition Facility. In July 2024, the Acquisition Facility was repaid in full with the net proceeds of secured term loans from a syndicate of lenders in the principal amount of \$48,500 and the remaining amount from cash on hand. As a result, the \$48,500 was reclassified to long-term debt as of June 30, 2024. Refer to Note 19 - Subsequent Events for more information.

Mortgage loans

The Company's three mortgage loan agreements contain certain financial and other covenants with which the Company is required to comply. As of June 30, 2024, the Company was in compliance with all financial covenants contained in each of the mortgage loan agreements.

Annual Maturities

In July 2024, the Company repaid the outstanding principal balance of its Acquisition Facility in full. The maturity table below reflects the portion of the Acquisition Facility that was refinanced with secured term loans from a syndicate of lenders, and the respective maturity date. Refer to Note 19 - Subsequent Events for more information. As of June 30, 2024, aggregate future scheduled repayments of the Company's debt were as follows:

| | ainder of e year | 2025 | 2026 | 2027 | 2028 | Total |
|--|-------------------------|----------|------------|-----------|-----------|---------|
| Second Lien Notes | \$ — \$ | — \$ | 79,649 \$ | — \$ | — \$ | 79,649 |
| Acquisition Facility | 6,750 | 2,425 | 46,075 | | _ | 55,250 |
| Acquisition-related promissory notes payable | 3,750 | _ | _ | 22,114 | _ | 25,864 |
| Mortgage loans | 318 | 647 | 658 | 9,440 | 18,255 | 29,318 |
| Total debt subject to scheduled repayments | \$ 10,818 \$ | 3,072 \$ | 126,382 \$ | 31,554 \$ | 18,255 \$ | 190,081 |

The above table excludes the contractual maturities of the Company's promissory notes payable to Sammartino, as the repayment of these notes, if any, would arise in the context of a non-appealable final judgment by a court. Refer to Note 16 - Commitments and Contingencies for more information. Specifically, the promissory notes that were payable to Sammartino are as follows: \$16,500 in 2024 and \$5,000 in 2026. However, these balances were classified as long-term debt as of June 30, 2024 since the Company does not expect to repay these amounts within the next 12 months.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



Interest Expense

Interest expense, net is comprised of the following:

| | Three Months Ended June 30, | | | | Six Months Ended June 30, | | | |
|--|-----------------------------|-------|----|-------|---------------------------|----|--------|--|
| | | 2024 | | 2023 | 2024 | | 2023 | |
| Interest expense | | | | | | | | |
| Interest and accretion - Second Lien Notes | \$ | 2,927 | \$ | 2,584 | \$ 5,675 | \$ | 4,928 | |
| Interest and accretion - Finance lease liabilities | | 2,404 | | 2,598 | 5,072 | | 4,947 | |
| Interest and accretion - Promissory notes | | 1,282 | | 1,542 | 2,656 | | 3,078 | |
| Interest and accretion - Acquisition Facility | | 2,035 | | 2,671 | 4,187 | | 4,967 | |
| Interest and accretion - Mortgage loans and other financing activities | | 670 | | 625 | 1,376 | | 810 | |
| Capitalized interest | | _ | | (222) | _ | | (410) | |
| Total interest expense | | 9,318 | | 9,798 | 18,966 | | 18,320 | |
| Interest income | | (247) | | (8) | (351 |) | (10) | |
| Total interest expense, net | \$ | 9,071 | \$ | 9,790 | \$ 18,615 | \$ | 18,310 | |

9. DERIVATIVE LIABILITIES

The following table summarizes the change in the Company's derivative liabilities for the six months ended June 30, 2024.

| | · | Total Derivative Liabilities ⁽¹⁾ | | |
|-------------------------------|-------|--|--|--|
| Balance as of January 1, 2024 | \$ | 2,638 | | |
| Fair value changes | | (212) | | |
| Balance as of June 30, 2024 | \$ | 2,426 | | |

⁽¹⁾ Refer to Note 10 - Equity for the change in number of warrants during the six months ended June 30, 2024.

The Company's derivative liabilities are primarily comprised of derivative warrants ("Derivative Warrants"). These are warrants to purchase SVS of the Company and were previously issued in connection with the Company's 10% senior secured notes. The Derivative Warrants may be net share settled. As of June 30, 2024 and December 31, 2023, there were 37,862,922 Derivative Warrants outstanding, which consisted of (i) 29,972,000 warrants with exercise price of \$1.25 per warrant and expiration date in December 2024, (ii) 5,890,922 warrants with exercise price of \$1.00 per warrant and expiration date of December 2024, and (iii) 2,000,000 warrants with an exercise price of \$2.086 per warrant and expiration date in December 2026.

Derivative Warrants are considered derivative financial liabilities measured at fair value with all gains or losses recognized in profit or loss as the settlement amount for the Derivative Warrants may be adjusted during certain periods for variables that are not inputs to standard pricing models for forward or option equity contracts, i.e., the "fixed for fixed" criteria under ASC 815-40. The estimated fair value of the Derivative Warrants is measured at the end of each reporting period and an adjustment is reflected in fair value changes in derivatives in the consolidated statements of operations and comprehensive income (loss). These are Level 3 recurring fair value measurements. The estimated fair value of the Derivative Warrants was determined using the Black-Scholes model with stock price based on the OTCQX closing price of the Derivative Warrants issue date as of June 30, 2024 and December 31, 2023.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



The assumptions used in the fair value calculations as of the balance sheet dates presented include the following:

| | June 30, 2024 (unaudited) | December 31, 2023 |
|--|------------------------------|--------------------------|
| Stock price | \$0.56 | \$0.46 |
| Risk-free annual interest rate | 4.62% - 5.33% | 4.01% - 4.79% |
| Range of estimated possible exercise price | \$1.00 - \$2.086 | \$1.00 - \$2.086 |
| Weighted average volatility | 114% | 101% |
| Remaining life | 0.50 - 2.44 years | 1.00 - 2.90 years |
| Forfeiture rate | 0% | 0% |
| Expected annual dividend yield | 0% | 0% |

Volatility was estimated by using a weighting of the Company's historical volatility. The risk-free interest rate for the expected life of the Derivative Warrants was based on the yield available on government benchmark bonds with an approximate equivalent remaining term. The expected life is based on the contractual term. If any of the assumptions used in the calculation were to increase or decrease, this could result in a material or significant increase or decrease in the estimated fair value of the derivative liability. For example, the following table illustrates an increase or decrease in certain significant assumptions as of the balance sheet dates:

| | | | As o | of June 30, 2024 | | | | | | | |
|-------------|-------------|-------|------|---------------------------|----|---------------------------|-----------------|----|---------------------------|----|---------------------------|
| | (unaudited) | | | | As | of l | December 31, 20 | 23 | | | |
| | | Input | E | Effect of 10% Increase | Е | Effect of 10% Decrease | Input | ı | Effect of 10% Increase | ı | Effect of 10% Decrease |
| Stock price | \$ | 0.56 | \$ | 693 | \$ | (604) | \$ 0.46 | \$ | 637 | \$ | (574) |
| Volatility | | 114 % | | 634 | | (595) | 101 % | | 680 | | (643) |

10. EQUITY

Authorized, Issued and Outstanding

The authorized share capital of the Company consists of an unlimited number of SVS, Multiple Voting Shares, Super Voting Shares, and Preferred Shares. As of June 30, 2024, the Company had 196,643,264 SVS issued and outstanding and no Multiple Voting Shares, Super Voting Shares or Preferred Shares issued and outstanding.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



Warrants

Each warrant entitles the holder to purchase one SVS. Certain warrants may be net share settled. The following table summarizes the status of warrants and related transactions:

| | Non-Derivative (Equity) Warrants | Derivative Liabilities Warrants | Total Number of Warrants | eighted - Average Exercise Price |
|---------------------------------|-------------------------------------|---------------------------------------|-----------------------------|-------------------------------------|
| Balance as of January 1, 2024 | 49,068,636 | 37,862,922 | 86,931,558 | \$ 1.12 |
| Granted (1) | 2,050,000 | | 2,050,000 | \$ 0.97 |
| Cancelled/forfeited/expired | (416,667) | _ | (416,667) | \$ 1.56 |
| Balance as of June 30, 2024 | 50,701,969 | 37,862,922 | 88,564,891 | \$ 1.12 |
| Exercisable as of June 30, 2024 | 49,141,969 | 37,862,922 | 87,004,891 | \$ 1.12 |

In February 2024, there were 1,800,000 warrants issued in connection with the Debt Exchange. Refer to Note 8 - Debt for more information.

The grant date fair value of the non-derivative warrants issued was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of issuance:

| Weighted average stock price | \$0.93 |
|--|-----------|
| Weighted average expected stock price volatility | 76.5% |
| Expected annual dividend yield | 0% |
| Weighted average expected life of warrants | 3.1 years |
| Weighted average risk-free annual interest rate | 4.1% |
| Weighted average grant date fair value | \$0.48 |

Share-based Payment Award Plans

Plan summary and description

Under the Company's 2019 Equity Incentive Plan, as amended, (the "2019 Plan"), non-transferable options to purchase SVS and restricted SVS of the Company may be issued to directors, officers, employees, or consultants of the Company. The 2019 Plan authorizes the issuance of up to 15% (plus an additional 2% inducements for hiring employees and senior management) of the number of outstanding shares of common stock (of all classes) of the Company (the "Share Reserve"). Incentive stock options are limited to the Share Reserve, and the maximum number of incentive awards available for issuance under the 2019 Plan, including additional awards available for certain new hires, was 6,817,474 as of June 30, 2024.

Stock Options

The stock options issued by the Company are options to purchase SVS of the Company. All stock options issued have been issued to directors and employees under the Company's 2019 Plan. Such options generally expire ten years from the date of grant and generally vest ratably over three years from the grant date. The options generally may be net share settled. The following table summarizes the status of stock options and related transactions:

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



| | Number of Stock Options | Weighted- Per Sl Exercise | hare |
|--|----------------------------|---------------------------------|------|
| Issued and Outstanding as of January 1, 2024 | 27,653,184 | \$ | 1.40 |
| Granted | 1,905,000 | \$ | 0.70 |
| Exercised | (11,666) | \$ | 0.60 |
| Cancelled/forfeited/expired | (2,936,498) | \$ | 1.70 |
| Issued and Outstanding as of June 30, 2024 | 26,610,020 | \$ | 1.31 |
| Exercisable as of June 30, 2024 | 16,531,064 | \$ | 1.61 |

The fair value of the stock options granted was determined using the Black-Scholes option-pricing model. The following assumptions were used for the calculation at date of grant:

| | Six Months En | ded June 30, |
|--|---------------|--------------|
| | 2024 | 2023 |
| Weighted average stock price | \$0.70 | \$0.51 |
| Weighted average expected stock price volatility | 77.9% | 76.9% |
| Expected annual dividend yield | 0% | 0% |
| Weighted average expected life | 5.1 years | 6.0 years |
| Weighted average risk-free annual interest rate | 4.3% | 3.6% |
| Weighted average grant date fair value | \$0.46 | \$0.34 |

Restricted Stock

The Company grants restricted SVS to independent directors, management, former owners of acquired businesses or assets, and to consultants and other employees. The restricted SVS are included in the issued and outstanding SVS, and the fair value of the restricted stock granted was estimated based on the SVS price at grant date. The following table summarizes the status of restricted stock and related transactions:

| | Number of Restricted Subordinate Voting Shares |
|---|--|
| Unvested restricted stock as of January 1, 2024 | 1,861 |
| Unvested restricted stock as of June 30, 2024 | 1,861 |

Generally, restricted stock awards will vest either one-third on each anniversary of service from the vesting start date or will be fully vested on the completion of one year of full service from the vesting start date, depending on the award.

Share-based Compensation Cost

The components of share-based compensation expense are as follows:

| | T | hree Months | Ende | d June 30, | Six Months Ended June 30, | | | | | |
|--|----|-------------|------|------------|---------------------------|-------|----|-------|--|--|
| | | 2024 2023 | | | | 2024 | | 2023 | | |
| Stock options | \$ | 594 | \$ | 1,862 | \$ | 1,949 | \$ | 3,458 | | |
| Restricted stock | | 1 | | 93 | | 2 | | 293 | | |
| Warrants | | (248) | | 408 | | (80) | | 923 | | |
| Total share-based compensation expense | \$ | 347 | \$ | 2,363 | \$ | 1,871 | \$ | 4,674 | | |

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



As of June 30, 2024, the Company had \$3,249 of unrecognized share-based compensation cost related to unvested stock options, restricted stock and warrants, which is expected to be recognized as share-based compensation cost over a weighted average period of 1.7 years.

11. EARNINGS (LOSS) PER SHARE

The reconciliations of the net loss and the weighted average number of shares used in the computations of basic and diluted loss per share are as follows:

| | | Three Months | End | led June 30, | Six Months Ended June 30, | | | | | |
|---|------|--------------|-----|--------------|---------------------------|-------------|----|-------------|--|--|
| | 2024 | | | 2023 | 2024 | | | 2023 | | |
| Numerator: | | | | | | | | | | |
| Net loss and comprehensive loss | \$ | (1,938) | \$ | (14,036) | \$ | (20,293) | \$ | (26,476) | | |
| Net loss and comprehensive loss - diluted | \$ | (1,938) | \$ | (14,036) | \$ | (20,293) | \$ | (26,476) | | |
| | | | | | | | | | | |
| Denominator: | | | | | | | | | | |
| Weighted-average shares of common stock - basic | | 195,138,473 | | 194,756,391 | | 195,135,057 | | 194,405,562 | | |
| Weighted-average shares of common stock - diluted | | 195,138,473 | | 194,756,391 | | 195,135,057 | | 194,405,562 | | |
| | | | | | | | | | | |
| Loss per common share: | | | | | | | | | | |
| Basic | \$ | (0.01) | \$ | (0.07) | \$ | (0.10) | \$ | (0.14) | | |
| Diluted | \$ | (0.01) | \$ | (0.07) | \$ | (0.10) | \$ | (0.14) | | |

The following table summarizes weighted average instruments that may, in the future, have a dilutive effect on earnings (loss) per share, but were excluded from consideration in the computation of diluted net loss per share for the three and six months ended June 30, 2024 and 2023, because the impact of including them would have been anti-dilutive:

| | Three Months E | nded June 30, | Six Months En | ided June 30, |
|--|----------------|---------------|---------------|---------------|
| | 2024 | 2023 | 2024 | 2023 |
| Stock options | 28,027,491 | 29,248,553 | 27,840,551 | 28,941,749 |
| Warrants (derivative liabilities and equity) | 88,564,891 | 86,097,189 | 88,237,693 | 86,043,865 |
| Unvested restricted stock awards | 1,861 | 376,980 | 1,861 | 746,843 |
| | 116,594,243 | 115,722,722 | 116,080,105 | 115,732,457 |

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



12. REVENUE

The Company has two revenue streams: (i) retail and (ii) wholesale. The Company's retail revenues are comprised of cannabis sales from its dispensaries. The Company's wholesale revenues are comprised of cannabis sales to its wholesale customers for resale through their dispensaries. Any intercompany revenue and costs are eliminated to arrive at consolidated totals.

The following table summarizes the Company's revenue from external customers, disaggregated by revenue stream:

| | Three Months Ended June 30, | | | | | Six Months Ended June 30, | | | | |
|--------------------|-----------------------------|--------|----|--------|----|---------------------------|----|---------|--|--|
| | | 2024 | | 2023 | | 2024 | | 2023 | | |
| Retail | \$ | 56,992 | \$ | 59,615 | \$ | 114,361 | \$ | 121,926 | | |
| Wholesale | | 7,603 | | 6,810 | | 15,693 | | 14,372 | | |
| Total revenue, net | \$ | 64,595 | \$ | 66,425 | \$ | 130,054 | \$ | 136,298 | | |

13. OPERATING EXPENSES

The major components of operating expenses are as follows:

| | | Three Months | Ende | d June 30, | Six Months Ended June 30, | | | | | |
|---|------|--------------|------|------------|---------------------------|--------|----|--------|--|--|
| | 2024 | | | 2023 | | 2024 | | 2023 | | |
| Salaries, wages and employee related expenses | \$ | 14,192 | \$ | 13,784 | \$ | 28,339 | \$ | 30,588 | | |
| Depreciation and amortization expense | | 3,827 | | 1,577 | | 7,105 | | 4,240 | | |
| Rent and related expenses | | 2,961 | | 2,504 | | 5,875 | | 5,397 | | |
| Professional fees and legal expenses | | 1,606 | | 2,321 | | 4,181 | | 4,646 | | |
| Share-based compensation expense | | 347 | | 2,363 | | 1,871 | | 4,674 | | |
| Other expenses (1) | | 1,229 | | 4,605 | | 5,002 | | 10,061 | | |
| Total operating expenses | \$ | 24,162 | \$ | 27,154 | \$ | 52,373 | \$ | 59,606 | | |

Other expenses are primarily comprised of marketing and selling expenses, insurance costs, administrative and licensing fees, software and technology costs, travel, gain/loss on lease terminations, gain/loss on asset disposals, entertainment and conferences and other.

14. INCOME TAXES

The following table summarizes the Company's income tax expense and effective tax rates for the three and six months ended June 30, 2024 and 2023:

| | Three Month | l June 30, | Six months ended June 30, | | | | |
|---------------------------------|-----------------|------------|---------------------------|------|------------|----|---------|
| | 2024 | 2023 | | 2024 | | | 2023 |
| Income (loss) before income tax | \$ 7,391 | \$ | (5,490) | \$ | (1,217) | \$ | (7,782) |
| Income tax expense | \$ 9,329 | \$ | 8,546 | \$ | 19,076 | \$ | 18,694 |
| Effective income tax rate | 126.2 % | | 6 155.7 % | | 6 1567.5 % | | 240.2 % |

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



The Company has computed its provision for income taxes based on the actual effective rate for the three and six months ended June 30, 2024 and 2023 as the Company believes this is the best estimate for the annual effective tax rate. Therefore, the Company's effective income tax rates for the three and six months ended June 30, 2024 and 2023 are not indicative of the effective income tax rate for each respective fiscal year of 2024 and 2023. The Company's effective income tax rate is significantly higher than the statutory income tax rates due in part to (i) an increase in the uncertain tax position liability due to tax positions based on legal interpretations that challenge the Company's tax liability under IRC Section 280E ("280E"), (ii) interest and penalties accrual for tax liabilities, and (iii) state income taxes.

The IRS has taken the position that cannabis companies are subject to the limitation of 280E, a position held by state tax regulators in Nevada, Ohio, Pennsylvania and Virginia. Under the IRS's interpretation of 280E, cannabis companies are only allowed to deduct expenses directly and indirectly related to the production of inventory.

In connection with the preparation and filing of the fiscal 2022 income tax return, the Company changed its previous application of 280E to exclude certain parts of its business. In regards to fiscal years 2023 and 2024, the Company has taken the position that it does not owe taxes attributable to the application of 280E. However, since the Company's tax positions on 280E may be challenged by taxing authorities, the Company elected to treat the deductibility of these related expenses as an uncertain tax position. As of June 30, 2024, the balances in income tax payable and unrecognized tax benefits on the consolidated balance sheets include the impact of the tax position on 280E, which decreased current liabilities with a corresponding increase in non-current liabilities. There is no material impact to the consolidated statements of operations and comprehensive income (loss).

The Company has a liability for unrecognized tax benefits of \$127,139 and \$100,343 as of June 30, 2024 and December 31, 2023, respectively, inclusive of interest and penalties. The Company anticipates that it is reasonably possible that its new tax position on 280E may require changes to the balance of unrecognized tax benefits within the next 12 months. However, an estimate of such changes cannot reasonably be made.

The total amount of interest and penalties related to the liability for unrecognized tax benefits recorded in income tax expense during the three and six months ended June 30, 2024 was \$2,277 and \$4,452, respectively. The total amount of interest and penalties related to the liability for unrecognized tax benefits recorded in income tax expense during the three and six months ended June 30, 2023 was \$644 and \$1,533, respectively.

15. RELATED PARTY TRANSACTIONS

The Company had the following related party transactions:

| | Th | Three Months Ended June 30, | | | Six Months En | As of | | | | |
|--|----|-----------------------------|-------|----|---------------|-----------------------|----|-------------------------|-----|-------------------|
| | | 2024 | 2023 | | 2024 | 2023 | | e 30, 2024 naudited) | Dec | ember 31, 2023 |
| Nature of transaction | | Related Party Expense | | | Related Part | Related Party Payable | | | | |
| 12% Second Lien Notes - interest expense and principal amount ⁽¹⁾ | \$ | (575) \$ | (563) | \$ | (1,152) | \$ (1,084) | \$ | (19,360) | \$ | (19,788) |
| Other debt (2) | \$ | — \$ | _ | \$ | _ | \$ — | \$ | | \$ | (3,298) |

For the periods ended June 30, 2024 and December 31, 2023, the Second Lien Notes payable and the related interest expense includes amounts related to the Company's Chief Executive Officer, as well as a significant investor.

Other debt relates to Jushi Europe which was deconsolidated during the three months ended June 30, 2024. Refer to Note 8 - Debt for more information.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



16. COMMITMENTS AND CONTINGENCIES

Contingencies

Although the possession, cultivation and distribution of cannabis for medical and recreational use is permitted in certain states, cannabis is classified as a Schedule-I controlled substance under the U.S. Controlled Substances Act and its use remains a violation of federal law. The Company's operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations. While management believes that the Company is in material compliance with applicable local and state regulations as of June 30, 2024, marijuana regulations continue to evolve and are subject to differing interpretations. As a result, the Company could be subject to regulatory fines, penalties or restrictions at any time. Since federal law criminalizing the use of cannabis preempts state laws that legalize its use, strict enforcement of federal law regarding cannabis would likely result in the Company's inability to proceed with the Company's business plans. A change in administration due to the upcoming United States presidential election presents a risk of a change in federal policy. In addition, the Company's assets, including real property, cash and cash equivalents, equipment, inventory and other goods, could be subject to asset forfeiture because cannabis is still federally illegal.

Refer to Note 14 - Income Taxes for certain tax-related contingencies.

Claims and Litigation

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2024, except as set forth below, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the Company's financial results. There are also no proceedings in which any of the Company's directors, officers or affiliates is an adverse party or has a material interest adverse to the Company's interest.

MJ Market matter

On March 31, 2023, MJ's Market, Inc. ("MJ's") filed a complaint in federal district court in Massachusetts adverse to Jushi Holdings Inc. and certain of its subsidiaries, including Jushi MA, Inc., Jushi Inc. and Nature's Remedy of Massachusetts, as well as the former owners and affiliates of Nature's Remedy of Massachusetts (the "Complaint"). The Complaint centrally claims that the structure of the Nature's Remedy of Massachusetts transaction providing for increased purchase price consideration if there is no competing dispensary within 2,500 foot radius by certain time periods, and the Company's filing with the Massachusetts Superior Court an appeal of the Town of Tyngsborough's decision to approve MJ's facility in contradiction of its own zoning bylaws are violations of the Sherman Antitrust Act, Massachusetts Antitrust Act, and Massachusetts Consumer Protection Act, as well as interference with contractual relations and abuse of process. MJ is seeking legal and equitable remedies including compensatory and other damages. The Company disputes such allegations, believes it has substantial defenses and is vigorously defending against the Complaint.

Sammartino Matter

On February 28, 2023, the Company informed Sammartino, the former owner of Nature's Remedy and certain of its affiliates, that Sammartino had breached several provisions of the MIPA and/or fraudulently induced the Company to enter into, and not terminate, the MIPA. As a consequence of these breaches and the fraudulent inducement, the Company informed Sammartino that the Company had incurred significant damages, and pursuant to the terms of the MIPA the Company had elected to offset these damages against certain promissory notes and shares the Company was to pay and issue, respectively, to Sammartino, and that Sammartino would be required to pay the remainder in cash. On March 13, 2023, Sammartino responded to the Company by alleging various procedural deficiencies with the Company's claim and provided the Company with a notice that the Company was in default of the MIPA for failing to issue certain shares of the Company to Sammartino. On March 21, 2023, Sammartino sent a second notice that the Company was in default of the

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



promissory notes for failing to pay interest pursuant to their specified schedule. On March 23, 2023, the Company sent a second letter to Sammartino disputing each procedural deficiency claimed by Sammartino and disputing that the Company is in default of the MIPA or the promissory notes and that it properly followed the terms of the various agreements in electing to set off the damages.

Pacific Collective matter

On October 24, 2022, Pacific Collective, LLC ("Pacific Collective") filed a complaint in state court in California against Jushi subsidiaries TGS CC Ventures, LLC ("TGS"), and Jushi Inc. Pacific Collective alleges that the Jushi subsidiaries breached a commercial property lease and lease guaranty and that Pacific Collective is entitled to recover in excess of \$20,000 in damages. TGS believes it lawfully rescinded the lease based on Pacific Collective's failure to purchase the property that was the subject of the lease and to construct and deliver the building contemplated by the lease and is of the position that no damages are owed to Pacific Collective. The Referee assigned to the matter ruled in favor of and awarded fees and costs to TGS and Jushi. Pacific Collective filed a notice of appeal on July 3, 2024.

Commitments

In addition to the contractual obligations outlined in Note 8 - Debt, the Company has commitments as of June 30, 2024 related to property and construction.

In connection with various license applications, the Company may enter into conditional leases or other property commitments which will be executed if the Company is successful in obtaining the applicable license and/or resolving other contingencies related to the license or application.

In addition, the Company expects to incur capital expenditures for leasehold improvements and construction of buildouts of certain locations, including for properties for which the lease is conditional on obtaining the applicable related license or for which other contingencies exist.

17. FINANCIAL INSTRUMENTS

The following table sets forth the Company's financial assets and liabilities, subject to fair value measurements on a recurring basis, by level within the fair value hierarchy:

| | ıne 30, 2024 unaudited) | Dec | cember 31, 2023 |
|--------------------------------------|----------------------------|-----|-----------------|
| Financial assets: (1) | | | |
| Equity investment (2) | \$ _ | \$ | 200 |
| Total financial assets | \$ _ | \$ | 200 |
| | | | |
| Financial liabilities: (1) | | | |
| Derivative liabilities (3) | \$ 2,426 | \$ | 2,638 |
| Contingent consideration liabilities | _ | | 817 |
| Total financial liabilities | \$ 2,426 | \$ | 3,455 |

The Company has no financial assets or liabilities in Level 1 or 2 within the fair value hierarchy as of June 30, 2024 and December 31, 2023, and there were no transfers between hierarchy levels during the six months ended June 30, 2024 or year ended December 31, 2023.

The Company adjusted its equity investment carrying value to reflect its equity balance of the investee, resulting in the recording of a loss on investment of \$200 for the three and six months ended June 30, 2024 and \$0 for the three and six months ended June 30, 2023. The loss on investment is included within other income (expense), net in the consolidated statements of operations and comprehensive income (loss).

⁽³⁾ Refer to Note 9 - Derivative Liabilities.

Notes to the Unaudited Condensed Consolidated Financial Statements (Amounts Expressed in Thousands of U.S. dollars, Except Share and Per Share Amounts)



The carrying amounts of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and certain accrued expenses, and certain other assets and liabilities held at amortized cost, approximate their fair values due to the short-term nature of these instruments. The equity investment approximates its fair value at June 30, 2024 and December 31, 2023. The carrying amounts of the promissory notes approximate their fair values as the effective interest rates are consistent with market rates. The carrying amount of the Second Lien Notes approximates their fair values as of June 30, 2024 and December 31, 2023, respectively.

18. SEGMENT INFORMATION

The Company operates a vertically integrated cannabis business in one reportable segment for the cultivation, manufacturing, distribution and sale of cannabis in the U.S. All of the Company's revenues were generated within the U.S., and substantially all long-lived assets are located within the U.S. The accounting policies for the Company's reportable segment are the same as those described in the summary of significant accounting policies. The chief operating decision maker is the Chief Executive Officer. The chief operating decision maker assesses performance and decides how to allocate resources based on operating results that are reported on the income statement as consolidated net income/ (loss). The measure of segment assets is reported on the balance sheet as total consolidated assets. Refer to Note 13 - Operating Expenses for significant expenses for the reportable segment.

19. SUBSEQUENT EVENTS

In July 2024, the Company extinguished one of its acquisition-related promissory notes which had a principal balance of \$3,750 as of June 30, 2024 and a maturity date of August 11, 2024. The promissory note was redeemed at 96 percent of the principal amount plus 50 percent of accrued and unpaid interest, resulting in a gain on extinguishment of \$140.

As of June 30, 2024, the Acquisition Facility principal balance was \$55,250 with a maturity date of December 2024. On July 1, 2024, the Company made a regularly scheduled principal payment of \$2,437, reducing the principal balance to \$52,813. On July 31, 2024, the Company refinanced its Acquisition Facility with a \$4,313 cash payment and \$48,500 in secured term loans from a syndicate of lenders, maturing in September 2026.

In July 2024, the state of Pennsylvania enacted legislation permitting medical cannabis businesses to deduct ordinary and necessary business expenses for state income tax purposes, which are disallowed under Internal Revenue Code Section 280E. This legislation is effective July 1, 2024, and applies to tax years beginning after December 31, 2023. As a result, the Company anticipates a reduction in state income tax expense beginning in fiscal year 2024. The Company estimates that this change will result in an annual state tax saving of approximately \$2,400, based on its current expense levels and a one-time benefit of approximately \$1,500.

In July 2024, the Company executed an agreement for the sale of one of its dispensaries at a sale price of \$3,000. This sale is subject to regulatory approvals and customary closing conditions, and is expected to be completed within the next nine months from June 30, 2024.